Avalyn Pharma is a technology company.
Avalyn Pharma has raised $316.0M across 3 funding rounds.
Avalyn Pharma has raised $316.0M in total across 3 funding rounds.
Avalyn Pharma has raised $316.0M in total across 3 funding rounds.
Avalyn Pharma's investors include B Capital Group, SR One, Heather Preston, Northpond Ventures.
Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for rare respiratory diseases, primarily idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). Their lead product candidate, AP01, is an inhaled formulation of pirfenidone designed to deliver medication directly to the lungs, aiming to improve efficacy and reduce systemic side effects compared to existing oral treatments. Avalyn serves patients suffering from severe, progressive lung scarring diseases that currently have limited treatment options, addressing a significant unmet medical need with innovative drug delivery. The company has shown growth momentum by advancing its pipeline into Phase 2b clinical trials and expanding its leadership team and investor base[1][2][3][6].
Avalyn Pharma was originally known as Genoa Pharmaceuticals and is headquartered in Seattle, Washington. The company was founded by Mark Surber, who serves as Chief Scientific Officer, with a team including experienced biopharma executives such as CEO Lyn Baranowski and Chief Medical Officer Howard Lazarus. The idea for Avalyn emerged from the need to improve treatment for pulmonary fibrosis by developing inhaled therapies that target the lungs directly, reducing systemic exposure and potentially improving patient outcomes. Early traction includes progressing AP01 into late-stage clinical development and securing investments from notable venture and growth capital firms like F-Prime Capital and TPG Biotech[1][3][5].
Avalyn Pharma is riding the trend of precision and targeted drug delivery in biopharma, particularly the shift toward inhaled therapies for respiratory diseases. This approach aligns with growing recognition that localized delivery can enhance treatment effectiveness and reduce systemic toxicity. The timing is critical as pulmonary fibrosis and related ILDs are increasingly diagnosed, and current oral therapies have limitations in efficacy and tolerability. Market forces such as an aging population, rising incidence of chronic lung diseases, and advances in inhalation technology favor Avalyn’s approach. By advancing inhaled formulations, Avalyn influences the broader ecosystem by pushing innovation in drug delivery methods and addressing rare diseases that are often underserved by traditional pharma[1][3][7].
Avalyn Pharma is positioned to advance its inhaled therapies through pivotal clinical trials, potentially reshaping treatment paradigms for pulmonary fibrosis and other ILDs. Future trends shaping their journey include increased focus on rare and orphan diseases, growing demand for patient-friendly drug delivery systems, and regulatory incentives for innovative therapies. As Avalyn progresses, its influence may expand beyond pulmonary fibrosis into other respiratory conditions, leveraging its inhalation platform. Continued clinical success and strategic partnerships will be key to unlocking commercial potential and broader impact in respiratory medicine.
Avalyn’s commitment to improving outcomes for patients with devastating lung diseases through innovative inhaled therapies underscores its role as a pioneering biopharma company in a critical and evolving therapeutic area[1][2][3][6][7].
Avalyn Pharma has raised $316.0M across 3 funding rounds. Most recently, it raised $100.0M Series D in July 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2025 | $100.0M Series D | B Capital Group, SR One, Heather Preston | |
| Sep 1, 2023 | $180.0M Series C | B Capital Group, Northpond Ventures, SR One, Heather Preston | |
| Apr 1, 2020 | $36.0M Series B | B Capital Group, Northpond Ventures, SR One |